In 2018, Justin Fulcher sold a majority stake in RingMD and spent approximately a year managing the transition, which included relocating the company’s headquarters from Singapore to Boston. For a founder who had built the platform from a solo prototype, the decision required careful reasoning about what the business needed next.

A Sale as a Scaling Decision

Justin Fulcher has framed the sale not as an exit but as a deliberate move to access capital and partners better positioned to take RingMD to its next stage. “Selling a company can be one of the best things for a business, or it can be a very negative thing, depending on alignment of values,” he has said. “What selling a company ultimately comes down to is a shared vision.” At the time, he described the transaction as a continuation rather than a departure. “This is a continuation of the vision rather than a departure from it.” The relaunched US-focused platform sharpened its positioning around government and institutional clients, trading the broad consumer marketplace of the Singapore era for a compliance-first approach built for regulated environments.

What Followed the Sale

The trajectory of RingMD after the sale confirmed the logic behind it. The platform secured the Indian Health Service contract, earned FedRAMP authorization, and continued expanding through institutional channels that required the kind of compliance infrastructure the restructured company was now equipped to deliver. Justin Fulcher stepped back from RingMD entirely in January 2025, by which point the platform was active in more than fifty countries and held 1.5 million patient records. The instinct to hold on is common among founders. Fulcher’s experience with RingMD suggests that recognizing when a company needs different capital or a different structure, and acting on that clearly, is one of the more consequential decisions a founder can make. Refer to this page to learn more.

Follow for more about Justin Fulcher on  https://www.instagram.com/justinfulcher/?hl=en